Positron emission tomography for use in microdosing studies

Wagner, C. C., Muller, M., Lappin, Graham and Langer, O. (2008) Positron emission tomography for use in microdosing studies. Current Opinion in Drug Discovery and Development, 11 (1). pp. 104-110. ISSN 1367-6733

Full content URL: http://www.ncbi.nlm.nih.gov/pubmed/18175273

Full text not available from this repository.

Item Type:Article
Item Status:Live Archive


Positron emission tomography (PET) imaging using microdoses of radiolabeled drug tracers is gaining increasing acceptance in modern clinical drug development. This approach is unique in that it allows for direct quantitative assessment of drug concentrations in the tissues targeted for treatment, thereby bridging the gap between pharmacokinetics and pharmacodynamics. Current applications of PET in anticancer, anti-infective and central nervous system drug research are reviewed herein. Situated at the interface of preclinical and clinical drug testing, PET microdosing is a powerful and highly innovative tool for pharmaceutical development. © The Thomson Corporation.

Keywords:5 fluoro 3 3 4 (5 methoxy 4 pyrimidinyl) 1 piperazinyl]propyl] 1h indole, amyloid, antiinfective agent, antineoplastic agent, carbon 11, central nervous system agents, DNA topoisomerase inhibitor, dopamine 2 receptor, dopamine 3 receptor, fluorine 18, fluorouracil, gyrase inhibitor, quinoline derived antiinfective agent, raclopride, st 1859, tracer, unclassified drug, drug research, human, liquid chromatography, nonhuman, pharmacodynamics, positron emission tomography, quantitative analysis, review, tandem mass spectrometry, Animals, Dose-Response Relationship, Drug, Drug Design, Humans, Pharmaceutical Preparations, Pharmacokinetics, Pharmacology, Positron-Emission Tomography, Radiopharmaceuticals
Divisions:College of Science > School of Pharmacy
Related URLs:
ID Code:8227
Deposited On:29 Mar 2013 12:09

Repository Staff Only: item control page